$174.400
+5.023 (+2.88%)終値時点
AZN のニュース
AZN のイベント
AstraZeneca Launches New Public Health Campaign
AstraZeneca announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask about biomarker testing if they or a loved one is diagnosed with cancer, helping make biomarker testing a standard part of the cancer care conversation.
Enhertu Approved in EU for HER2 Positive Breast Cancer Treatment
Enhertu has been approved in the European Union, or EU, as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Amgen and AstraZeneca's Combination Therapy Reduces Death Risk by 58% in Small Cell Lung Cancer
Amgen (AMGN) announced an interim Phase 3 results showing that Imdelltra in combination with AstraZeneca's (AZN) Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer at a median follow-up of approximately 16 months. The DeLLphi-305 study found that Imdelltra in combination with durvalumab extended median overall survival, OS, by more than eight months to 21.1 months compared with 12.7 months with durvalumab alone for patients with ES-SCLC who had not progressed following initial treatment with durvalumab, platinum-based chemotherapy and etoposide. The data are being presented during a Presidential Symposium at the European Society for Medical Oncology, ESMO, Congress 2026 and simultaneously published in The New England Journal of Medicine.
AstraZeneca's Tagrisso Plus Savolitinib Significantly Improves Survival in NSCLC Patients
AstraZeneca announces positive results from the SAFFRON Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival, PFS, and overall survival, OS, versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer, NSCLC. These results will be presented during the Presidential Symposium at the European Society for Medical Oncology, ESMO, Congress 2026 in Madrid, Spain. Results showed Tagrisso plus savolitinib reduced the risk of disease progression or death by 45% compared to chemotherapy. Median PFS as assessed by blinded independent central review, BICR, was 7.6 months for TAGRISSO plus savolitinib versus 5.4 months for the comparator arm. An estimated 36% of patients treated with the combination were progression-free at one year compared to 10% in the comparator arm. Results for the key secondary endpoint of OS showed TAGRISSO plus savolitinib reduced the risk of death by 32% versus chemotherapy. TAGRISSO plus savolitinib extended median OS by 4.9 months versus the comparator arm. An estimated 70% of patients treated with the combination were alive at one year compared to 53% in the comparator arm.
AstraZeneca's Sone-Ve Significantly Improves Survival in Phase III Trial
Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival, OS, in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator's choice of therapy. The trial included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction, GEJ, cancer, or esophageal adenocarcinoma with Claudin 18.2 expression on at least 25% of tumor cells at any staining intensity, expanding the patient population beyond the current definition of CLDN18.2 positivity. The trial had dual primary endpoints of OS in the 3rd- and later-line treatment setting and progression-free survival, PFS, in the overall trial population of patients treated in the 2nd- and later-line setting. OS in the overall trial population was a key secondary endpoint. In a planned interim analysis, Sone-Ve reduced the risk of death by 42% compared to investigator's choice of therapy in the overall trial population. In the 3rd- and later-line setting, Sone-Ve reduced the risk of death by 53% compared to investigator's choice of therapy. Median OS doubled for patients treated with Sone-Ve.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。